Lilly's Quest for COVID-19 Treatments:
EXISTING MEDICINES

Lilly is studying baricitinib as a potential treatment for COVID-19 in certain hospitalized patients.

Clinical trials are evaluating the efficacy and safety of baricitinib.
The timing for data disclosure from these trials is dependent on patient enrollment.

	ACTT-2	ACTT-4	COV-BARRIER (KHAA)
STAGE OF COVID-19 ILLNESS	Hospitalized	Hospitalized	Hospitalized
DRUG	Baricitinib + remdesivir vs. placebo + remdesivir	Baricitinib + remdesivir vs. dexamethasone + remdesivir	Baricitinib + placebo
PHASE(S)	Phase 3	Phase 3	Phase 3
TRIAL TYPE	Randomized, double-blind, placebo-controlled trial	Randomized, double-blind, trial with active comparator	Randomized, double-blind, placebo-controlled trial
TRIAL GOAL(S)	Evaluate time to recovery in patients treated with baricitinib + remdesivir vs. placebo + remdesivir	Evaluate mortality and need of mechanical ventilation in patients treated with baricitinib + remdesivir vs. dexamethasone + remdesivir	Evaluate mortality and need for ventilation in patients treated with baricitinib + SOC vs. placebo + SOC
PARTICIPANTS	Hospitalized adults with or without oxygen requirements	Hospitalized adults requiring oxygen	Hospitalized adults with or without oxygen requirement; excludes patients requiring invasive mechanical ventilation or ECMO
# OF PARTICIPANTS (estimated)	1,033	1,500	1,000
LOCATION	U.S., Denmark, Japan, Korea, Mexico, Singapore, Spain, UK	U.S. and other countries	U.S., Argentina, Brazil, Germany, India, Italy, Japan, Korea, Mexico, Puerto Rico, Russia, Spain, UK
STUDY STATUS	Complete Data submitted to FDA as part of "Request for Emergency Use Authorization"	Ongoing	Ongoing
SPONSOR	• National Institute of Allergy and Infectious Diseases (NIAID)	• National Institute of Allergy and Infectious Diseases (NIAID)	• Lilly

The fastest path to discovery and the most effective way to fight disease is often through collaboration and partnership.

Lilly + + +

Lilly is committed to working with academic researchers, health care professionals, hospitals and governments to investigate the potential use of an existing medicine to treat COVID-19.

For more information, refer to the listings above on clinicaltrials.gov or visit lilly.com.